CLEVER LEAVES HOLDINGS INC (CLVR)
CA1867602031 - Common Stock
Overall CLVR gets a fundamental rating of 2 out of 10. We evaluated CLVR against 196 industry peers in the Pharmaceuticals industry. CLVR may be in some trouble as it scores bad on both profitability and health. CLVR is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CLVR has reported negative net income.
In the past year CLVR has reported a negative cash flow from operations.
In the past 5 years CLVR always reported negative net income.
CLVR had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -57.31%, CLVR is doing worse than 62.56% of the companies in the same industry.
CLVR has a Return On Equity (-73.94%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -57.31% | ||
| ROE | -73.94% | ||
| ROIC | N/A |
ROA(3y)-74.55%
ROA(5y)-49.14%
ROE(3y)-100.17%
ROE(5y)-67.74%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CLVR's Gross Margin of 37.63% is in line compared to the rest of the industry. CLVR outperforms 56.41% of its industry peers.
In the last couple of years the Gross Margin of CLVR has declined.
CLVR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 37.63% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.93%
GM growth 5YN/A
2. Health
2.1 Basic Checks
CLVR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CLVR has been increased compared to 1 year ago.
Compared to 5 years ago, CLVR has more shares outstanding
CLVR has a worse debt/assets ratio than last year.
2.2 Solvency
CLVR has an Altman-Z score of -9.24. This is a bad value and indicates that CLVR is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CLVR (-9.24) is worse than 76.41% of its industry peers.
CLVR has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.03, CLVR is in line with its industry, outperforming 51.28% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.24 |
ROIC/WACCN/A
WACC10.07%
2.3 Liquidity
A Current Ratio of 2.40 indicates that CLVR has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.40, CLVR is doing worse than 60.00% of the companies in the same industry.
A Quick Ratio of 1.63 indicates that CLVR should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.63, CLVR is doing worse than 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.4 | ||
| Quick Ratio | 1.63 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 78.15% over the past year.
CLVR shows a small growth in Revenue. In the last year, the Revenue has grown by 4.80%.
The Revenue has been growing by 12.85% on average over the past years. This is quite good.
EPS 1Y (TTM)78.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.01%
Revenue 1Y (TTM)4.8%
Revenue growth 3Y12.85%
Revenue growth 5YN/A
Sales Q2Q%0.61%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
Based on estimates for the next years, CLVR will show a very strong growth in Revenue. The Revenue will grow by 128.91% on average per year.
EPS Next Y29.03%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year50%
Revenue Next 2Y128.92%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CLVR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CLVR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for CLVR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CLEVER LEAVES HOLDINGS INC
NASDAQ:CLVR (5/16/2024, 8:00:00 PM)
After market: 3.05 +0.05 (+1.67%)3
+0.89 (+42.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.25M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -57.31% | ||
| ROE | -73.94% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 37.63% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.4 | ||
| Quick Ratio | 1.63 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)78.15%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y29.03%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)4.8%
Revenue growth 3Y12.85%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y